Qlife reaches important milestone: launches Egoo Health and CRP test
As of February 15, 2023, the Egoo CRP Capsule will be the first product in Qlife’s Egoo portfolio to be introduced to the home market. The CRP test is soft-launched as a test without medical claims and will be followed by submission of the file for CE-mark, which allows for broader clinical applicability of the platform
With the launch of our CRP capsule, Qlife will start delivering on our vision of bringing lifestyle biomarker testing with quantitative precise data to a wider health conscious audience and for home use.
There is a growing demand and acceptance in the market for diagnostics self-testing. Now, health practitioners such as dieticians, nutritionists, physiotherapists and dentists can purchase the platform and assist in monitoring and interpretation of relevant biomarkers. Also, consumers will now be able to monitor and use the data in the context they wish, to optimize their athletic performance or to make necessary changes in lifestyle. Furthermore, Qlife will obtain CE-marks to broaden the clinical applicability of the platform.
“We are very excited to have reached this milestone. Our most important goal has always been to make Egoo Health available for non-professionals and for people in their home. The company is now taking this first step for general health empowerment to the people”, says Thomas Warthoe, CEO of Qlife.
The Egoo Health, both device and CRP capsules, will be available for all customers to order on the Egoo Health webshop as of February 15. Capsules are available as single orders or as subscriptions. Based on Qlife’s own information, this is the world's first self-test platform for immuno-diagnostics biomarkers.
Qlife was founded based on the idea that Egoo Health could help people lead a better life by using the diagnostics self-testing platform Egoo Health, Empowering a Better Being.